

|              |  |
|--------------|--|
| <b>Date:</b> | August 23, 2021  |
| <b>To:</b>   | NH physicians, nurses, and pharmacists                                       |
| <b>From:</b> | NH Therapeutics Committee  |
| <b>Re:</b>   | Tocilizumab (ACTEMRA) Injection for COVID-19; Updated Dosing Recommendations |

Due to the increasing COVID case hospital admissions in the province and a national supply shortage of Tocilizumab, the BC COVID-19 Therapeutics Committee (CTC) has once again revised their clinical practice guidance regarding tocilizumab injection dosing for the treatment of patients with severe COVID-19 requiring life support measures.

Our current order set will be changed back to a fixed dosing strategy of tocilizumab 400 mg IV x 1 dose. Clinical criteria for use remains unchanged at this time. The [updated NH order](#) set and parenteral drug monograph available on [OurNH](#) have been updated to reflect this new dosing strategy. The order set will also be posted on the COVID section of physician website.

For more information on NH supply and availability contact: NH Regional Medication Use Management Pharmacist [mumpharmacist@northernhealth.ca](mailto:mumpharmacist@northernhealth.ca)